Preview

Medical Herald of the South of Russia

Advanced search

The influence of xenon-therapy on tolerance of adjuvant radiotherapy in patients with single brain metastasis

https://doi.org/10.21886/2219-8075-2018-9-1-32-41

Abstract

Objective: to study the tolerance of radiotherapy by adding the boost and the xenon-therapy during the whole brain radiotherapy (WBRT) in patients with single brain metastasis. Materials and methods: the study involved 60 patients divided in the 3 equal groups (20 people in each group) where the treatment varied according the methods of the adjuvant radiotherapy. The patients in the first group were assigned to receive WBRT alone, in the second group — WBRT and the boost to tumor bed, in the third group — WBRT and the boost in combination with the xenon-oxygen inhalations. The quality of life, the toxic and adaptation reaction, the psychological status and the electrical activity of the brain during the treatment were also included in the research. Results: the increase of side-effects of the treatment and the quantity of stress-reactions occurred during WBRT in combination with the boost. But the use of xenon allowed to level all the negative reactions and even to improve some of physiological and psychological parameters. The xenon-oxygen inhalations led to the decrease of intensity of situational anxiety and depression. There was also a reduction in delta-activity level according to EEG and a return of the other rhythms to baseline levels which was lacking in the other groups. Conclusions: the use of the xenon-therapy in combination with WBRT by the developed methods allows to improve the quality of life in patients with radiation treatment, as well as to reduce the degree of the intensity of side and toxic reactions. The results of objective methods at the trial demonstrate the stresseless and radioprotective effects of xenon.

About the Authors

M. S. Zinkovich
Rostov Research Institute of Oncology, Rostov-on-Don
Russian Federation
radiotherapist of Radiology Department
Competing Interests: Авторы заявляют об отсутствии конфликта интересов


L. Y. Rozenko
Rostov Research Institute of Oncology, Rostov-on-Don
Russian Federation
PhD, D.Med.Sci., Professor, radiotherapist of Radiology Department
Competing Interests: Авторы заявляют об отсутствии конфликта интересов


A. I. Shikhlyarova
Rostov Research Institute of Oncology, Rostov-on-Don
Russian Federation
PhD, D.Biol.Sci., Professor, Head of Experimental Laboratory Center
Competing Interests: Авторы заявляют об отсутствии конфликта интересов


G. V. Gukova
Rostov Research Institute of Oncology, Rostov-on-Don
Russian Federation
PhD, D.Biol.Sci., senior researcher of Experimental Laboratory Center
Competing Interests: Авторы заявляют об отсутствии конфликта интересов


Y. Y. Arapova
Rostov Research Institute of Oncology, Rostov-on-Don
Russian Federation
PhD, researcher of Experimental Laboratory Center
Competing Interests: Авторы заявляют об отсутствии конфликта интересов


T. P. Protasova
Rostov Research Institute of Oncology, Rostov-on-Don
Russian Federation
PhD, senior researcher of Experimental Laboratory Center
Competing Interests: Авторы заявляют об отсутствии конфликта интересоврос


References

1. Golanov AV, Banov SM, Il’yalov SR, Vetlova ER, Smolin AV, et al. Treatment of patients with brain metastases. Zh Vopr Neirokhir Im N N Burdenko. 2016;80(4):89-101. (in Russ.) doi: 10.17116/neiro201680489-100

2. Lin L, Zhao CH, Ge FJ, Wang Y, Chen YL, et al. Patients with brain metastases derived from gastrointestinal cancer: clinical characteristics and prognostic factors. Clin and Translat Oncol. 2016;18(1):93–98. doi: 10.1007/s12094-015-1341-8.

3. Furtner J, Berghoff AS, Albtoush OM, Woitek R, Asenbaum U, et al. Survival prediction using temporal muscle thickness measurements on cranial magnetic resonance images in patients with newly diagnosed brain metastases. European Radiology. 2017;27(8):3167-3173. doi: 10.1007/s00330-016-4707-6.

4. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA. 2006;295(21):2483–2491. doi: 10.1001/jama.295.21.2483.

5. Chang EL, Wefel JS, Hess K, Allen PK, Lang FF, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus WBRT. Lancet Oncol. 2009;10(11):1037–1044. doi: 10.1016/s1470-2045(09)70263-3.

6. Chabot P, Hsia TC, Ryu JS, Gorbunova V, Belda-Iniesta C, et al. Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study. Journal of Neuro-Oncology. 2016;131(1):105–115. doi: 10.1007/s11060-016-2275-x.

7. Asai A, Kawamoto K. Radiation-induced brain injury. Brain Nerve. 2008;60(2):123–129. doi: 10.11477/mf.1416100219.

8. Sanghvi SM, Lischalk JW, Ling Cai, Collins S, Nair M, et al. Clinical outcomes of gastrointestinal brain metastases treated with radiotherapy. Radiat Oncol. 2017;12(1):43–52. doi: 10.1186/s13014-017-0774-3.

9. Rades D, Janssen S, Bajrovic A, Khoa MT, Veninga T, Schild S. A matched-pair analysis comparing whole-brain radiotherapy with and without a stereotactic boost for intracerebral control and overall survival in patients with one to three cerebral metastases. Radiat Oncol. 2017;12(1):69. doi: 10.1186/s13014-017-0804-1.

10. Dovgusha VV, Dovgusha LV. Anomal’nye dinamicheskie svoistva gazov, vliyayushchikh na biologicheskie sistemy. SPb.: OOO Press-servis; 2013. (In Russ).


Review

For citations:


Zinkovich M.S., Rozenko L.Y., Shikhlyarova A.I., Gukova G.V., Arapova Y.Y., Protasova T.P. The influence of xenon-therapy on tolerance of adjuvant radiotherapy in patients with single brain metastasis. Medical Herald of the South of Russia. 2018;9(1):32-41. (In Russ.) https://doi.org/10.21886/2219-8075-2018-9-1-32-41

Views: 741


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2219-8075 (Print)
ISSN 2618-7876 (Online)